Biocept Inks Research Pact With Protean BioDiagnostics For Target Selector Kit Advantages In Lung Cancer

Biocept Inc (NASDAQ: BIOC) will collaborate with Protean BioDiagnostics Inc to research Biocept's Target Selector molecular assay's ability to determine EGFR status in non-small cell lung cancer (NSCLC) patients.
The research will be conducted in an independent pathology laboratory setting.
Protean BioDiagnostics also expects to validate a laboratory-developed test's analytical performance based on Biocept's EGFR assay test kit.
Biocept's molecular assay kit, available for research-use-only and with CE-IVD mark, is used to analyze both formalin-fixed paraffin-embedded tissue samples and circulating tumor DNA from biological fluids.
The molecular assays have been validated to detect frequent oncogenic mutations EGFR, KRAS, and BRAF, which are the most frequently evaluated biomarkers for lung cancer and melanoma.
Price Action: BIOC stock is down 9.2% at $6.5 in market trading hours on the last check Tuesday.